Small Molecules

18 Oct 2017 U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
17 Oct 2017 Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer
17 Oct 2017 MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC
17 Oct 2017 Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases
17 Oct 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
17 Oct 2017 Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial
17 Oct 2017 Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
17 Oct 2017 Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
16 Oct 2017 Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer
14 Oct 2017 Faslodex (fulvestrant) receives positive CHMP opinion for the treatment of hormone receptor-positive advanced breast cancer in combination with palbociclib1
14 Oct 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
13 Oct 2017 CHMP Issues a Positive Opinion on Janssen’s ZYTIGA® to Include Earlier Stage Prostate Cancer Patients
12 Oct 2017 Spinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients
12 Oct 2017 Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis
12 Oct 2017 U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV
12 Oct 2017 FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
12 Oct 2017 Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
12 Oct 2017 Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
12 Oct 2017 Merck Provides Update on Anacetrapib Development Program
11 Oct 2017 Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
11 Oct 2017 Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
11 Oct 2017 MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris
11 Oct 2017 Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
10 Oct 2017 Abide Therapeutics Announces Dosing of First Subject in Phase 1b Study of ABX-1431 in Patients with Neuromyelitis Optica (NMO)
10 Oct 2017 Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing